Meeder Asset Management Inc. raised its holdings in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 3,735.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,603 shares of the company’s stock after acquiring an additional 4,483 shares during the quarter. Meeder Asset Management Inc.’s holdings in Pacira Pharmaceuticals were worth $198,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its position in Pacira Pharmaceuticals by 9.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 213,224 shares of the company’s stock valued at $6,834,000 after acquiring an additional 17,950 shares during the last quarter. Raymond James & Associates grew its position in shares of Pacira Pharmaceuticals by 21.7% during the 2nd quarter. Raymond James & Associates now owns 21,611 shares of the company’s stock worth $693,000 after buying an additional 3,850 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Pacira Pharmaceuticals by 1,925.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock worth $214,000 after buying an additional 6,336 shares in the last quarter. Schroder Investment Management Group grew its position in shares of Pacira Pharmaceuticals by 2.4% during the 2nd quarter. Schroder Investment Management Group now owns 1,255,030 shares of the company’s stock worth $38,969,000 after buying an additional 29,223 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Pacira Pharmaceuticals by 4.3% during the 2nd quarter. Northern Trust Corp now owns 512,082 shares of the company’s stock worth $16,412,000 after buying an additional 20,877 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.
In other Pacira Pharmaceuticals news, Director Gary W. Pace purchased 4,500 shares of the firm’s stock in a transaction on Monday, November 19th. The stock was bought at an average cost of $46.18 per share, for a total transaction of $207,810.00. Following the completion of the purchase, the director now owns 32,819 shares in the company, valued at approximately $1,515,581.42. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andreas Wicki sold 14,527 shares of the stock in a transaction dated Thursday, December 13th. The shares were sold at an average price of $46.84, for a total value of $680,444.68. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Mizuho downgraded Pacira Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research report on Friday, February 1st. ValuEngine downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 20th. HC Wainwright increased their price target on Pacira Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research report on Friday, November 2nd. Finally, BMO Capital Markets increased their price target on Pacira Pharmaceuticals from $40.00 to $47.00 and gave the stock a “market perform” rating in a research report on Friday, November 2nd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $54.31.
Pacira Pharmaceuticals stock traded up $1.00 during midday trading on Friday, reaching $40.68. The company’s stock had a trading volume of 478,439 shares, compared to its average volume of 641,348. The company has a debt-to-equity ratio of 0.95, a quick ratio of 7.83 and a current ratio of 8.66. Pacira Pharmaceuticals Inc has a 52-week low of $26.95 and a 52-week high of $55.00. The stock has a market cap of $1.67 billion, a PE ratio of -70.14 and a beta of 1.55.
COPYRIGHT VIOLATION WARNING: “Meeder Asset Management Inc. Has $198,000 Position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX)” was originally posted by Highlight Press and is the property of of Highlight Press. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://highlightpress.com/2019/02/16/meeder-asset-management-inc-boosts-holdings-in-pacira-pharmaceuticals-inc-pcrx.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Further Reading: Why do companies issue stock splits?
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.